Renaissance Technologies LLC Has $10.88 Million Stock Holdings in MiMedx Group, Inc. (NASDAQ:MDXG)

Renaissance Technologies LLC cut its position in MiMedx Group, Inc. (NASDAQ:MDXG) by 10.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,570,585 shares of the company’s stock after selling 186,000 shares during the period. Renaissance Technologies LLC owned 1.06% of MiMedx Group worth $10,884,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Caxton Associates LP acquired a new stake in shares of MiMedx Group in the 1st quarter valued at about $1,018,000. Victory Capital Management Inc. lifted its position in MiMedx Group by 909.0% in the 2nd quarter. Victory Capital Management Inc. now owns 138,449 shares of the company’s stock valued at $959,000 after acquiring an additional 124,727 shares in the last quarter. Isthmus Partners LLC lifted its position in shares of MiMedx Group by 30.4% during the 2nd quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock worth $27,000 after buying an additional 91,714 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of MiMedx Group by 13.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 32,978 shares of the company’s stock worth $254,000 after buying an additional 3,806 shares in the last quarter. Finally, Entropy Technologies LP bought a new position in shares of MiMedx Group during the 1st quarter worth approximately $99,000. 79.15% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on MDXG shares. StockNews.com raised shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, September 4th. Craig Hallum dropped their target price on shares of MiMedx Group from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $11.00 target price on shares of MiMedx Group in a research report on Thursday, August 1st. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, MiMedx Group presently has an average rating of “Buy” and an average price target of $12.00.

MiMedx Group Stock Performance

NASDAQ:MDXG opened at $6.13 on Tuesday. The company has a current ratio of 3.85, a quick ratio of 3.22 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $904.81 million, a PE ratio of 13.93 and a beta of 1.98. The firm’s 50 day moving average is $6.67 and its 200 day moving average is $7.00. MiMedx Group, Inc. has a 12 month low of $5.57 and a 12 month high of $9.27.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings data on Wednesday, July 31st. The company reported $0.08 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.08. MiMedx Group had a net margin of 23.63% and a return on equity of 34.24%. The business had revenue of $87.21 million during the quarter, compared to analyst estimates of $88.44 million. Sell-side analysts expect that MiMedx Group, Inc. will post 0.26 earnings per share for the current year.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.